Health care professionals ‘thrilled’ with approval of first treatment for MASH
More than 1,600 health care professionals celebrated the approval of Rezdiffra, the first treatment for adults with metabolic dysfunction-associated steatohepatitis, according to a global online conversation analysis by Creation Healthcare. Rezdiffra (resmetirom, Madrigal Pharmaceuticals) was granted accelerated approval by the FDA on March 14, and became available to U.S. pharmacies on April 9.